EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Myriad Genetics's enterprise value is $1,683.3 Mil.
Myriad Genetics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-197.4 Mil. Therefore, Myriad Genetics's EV-to-EBITDA for today is -8.53.
The historical rank and industry rank for Myriad Genetics's EV-to-EBITDA or its related term are showing as below:
MYGN'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -42.89 Med: 11.57 Max: 248.88
Current: -8.53
During the past 13 years, the highest EV-to-EBITDA of Myriad Genetics was 248.88. The lowest was -42.89. And the median was 11.57.
MYGN's EV-to-EBITDA is ranked worse than 100% of 120
companies
in the Medical Diagnostics & Research industry
Industry Median: 15.16
vs MYGN: -8.53
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-18), Myriad Genetics's stock price is $18.67.
Myriad Genetics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.200. Therefore, Myriad Genetics's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Myriad Genetics EV-to-EBITDA Historical Data
The historical data trend for Myriad Genetics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Myriad Genetics Annual Data
Trend
Jun14
Jun15
Jun16
Jun17
Jun18
Jun19
Jun20
Dec21
Dec22
Dec23
EV-to-EBITDA
25.16
-6.58
159.47
-14.27
-8.77
Myriad Genetics Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
EV-to-EBITDA
-14.27
-18.84
-9.77
-6.55
-8.77
Competitive Comparison
For the Diagnostics & Research subindustry, Myriad Genetics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Myriad Genetics EV-to-EBITDA Distribution
For the Medical Diagnostics & Research industry and Healthcare sector, Myriad Genetics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Myriad Genetics's EV-to-EBITDA falls into.
Myriad Genetics EV-to-EBITDA Calculation
Myriad Genetics's EV-to-EBITDA for today is calculated as:
Myriad Genetics's current Enterprise Value is $1,683.3 Mil.
Myriad Genetics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-197.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Myriad Genetics's PE Ratio for today is calculated as:
Myriad Genetics's share price for today is $18.67.
Myriad Genetics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.200.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Myriad Genetics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Myriad Genetics (Myriad Genetics) Business Description
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MYGN has been successfully added to your 